The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural/pericardial effusion, ANA positive (DI lupus)
Publications
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Rheumatology (Oxford, England) 2011 Jan;50;222-9 — 2011 Jan — 222-9
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
Mayo Clinic proceedings 2009 Nov;84;979-84 — 2009 Nov — 979-84
Porfyridis I, Kalomenidis I, Psallidas I, Stratakos G, Roussos C, Vassilakopoulos T, Stathopoulos GT
Etanercept-induced pleuropericardial lupus-like syndrome.
The European respiratory journal 2009 Apr;33;939-41 — 2009 Apr — 939-41
[Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
Medizinische Klinik (Munich, Germany : 1983) 2007 Oct 15;102;852-7 — 2007 Oct 15 — 852-7